Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more
Yungjin Pharm Co Ltd (003520) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.078x
Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) has a cash flow conversion efficiency ratio of 0.078x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.00 Billion) by net assets (₩90.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Yungjin Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Yungjin Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Yungjin Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yungjin Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PCA Corporation
PINK:PCRDF
|
N/A |
|
Alumil Aluminium Industry S.A
AT:ALMY
|
0.021x |
|
Supermax Corporation Bhd
KLSE:7106
|
0.001x |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
0.156x |
|
WAWEL SA
WAR:WWL
|
0.019x |
|
China Boton Group Company Limited
PINK:CHBGF
|
N/A |
|
KOGENERACJA S.A. ZY 5
F:2ZO
|
N/A |
|
Profile Systems & Software SA
AT:PROF
|
0.011x |
Annual Cash Flow Conversion Efficiency for Yungjin Pharm Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Yungjin Pharm Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩89.80 Billion | ₩21.74 Billion | 0.242x | +312.24% |
| 2023-12-31 | ₩89.63 Billion | ₩-10.22 Billion | -0.114x | +11.70% |
| 2022-12-31 | ₩89.87 Billion | ₩-11.61 Billion | -0.129x | -261.92% |
| 2021-12-31 | ₩104.89 Billion | ₩8.37 Billion | 0.080x | -37.03% |
| 2020-12-31 | ₩114.43 Billion | ₩14.50 Billion | 0.127x | +57.98% |
| 2019-12-31 | ₩115.75 Billion | ₩9.28 Billion | 0.080x | +602.43% |
| 2018-12-31 | ₩111.61 Billion | ₩1.27 Billion | 0.011x | -56.66% |
| 2017-12-31 | ₩119.65 Billion | ₩3.15 Billion | 0.026x | -10.13% |
| 2016-12-31 | ₩106.17 Billion | ₩3.11 Billion | 0.029x | -66.56% |
| 2015-12-31 | ₩100.42 Billion | ₩8.80 Billion | 0.088x | +42.11% |
| 2014-12-31 | ₩100.79 Billion | ₩6.22 Billion | 0.062x | +6.13% |
| 2013-12-31 | ₩102.45 Billion | ₩5.95 Billion | 0.058x | -- |